Heard: Bill to protect 340B drug program access draws broad, divided testimony
SB 5,981 would prohibit manufacturers from restricting acquisition or delivery of 340B drugs to covered entities or contract pharmacies (unless federal law requires such limits) and would bar manufacturers from demanding claims or utilization data as a condition of participation; hospital systems, community health centers, tribal clinics and manufacturers offered sharply divergent testimony.
The full story
Senate Bill 5,981 drew extended testimony Jan. 16. The bill would prohibit drug manufacturers or distributors from denying, restricting or prohibiting acquisition or delivery of a 340B drug by a covered entity or a contract pharmacy unless federal law requires such restriction, and would bar manufacturers from conditioning 340B access on submission of claims, utilization or purchasing data unless federal law requires it. The bill would allow covered entities to sue to enjoin violations and permits the Attorney General to bring actions on behalf of the state.
Sign up to keep reading.
Your free newsletter brings you what your city council, county, and school board discussed and decided.